Skip to main content

Table 1 Baseline values, ranges, and distributions for sensitivity analysis

From: Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China

Variable Value Range Distribution
AEs with fruquintinib
 Hypertension
 Hand-foot syndrome
 Diarrhea
 Platelet count decreased
0.212
0.108
0.029
0.025
0.170 to 0.254
0.086 to 0.130
0.0232 to 0.0348
0.02 to 0.03
Beta
Beta
Beta
Beta
AEs with best supportive care
 Hypertension 0.022 0.0176 to 0.0264 Beta
Cost of best supportive care 1415.4 1022.8 to 2021.5 Gamma
Cost of fruquintinib after price negotiation 1128.8 903.0 to 1354.5 Gamma
Cost of fruquintinib before price negotiation 3408.5 2726.8 to 4090.2 Gamma
AE cost, USD
 Hypertension
 Hand-foot syndrome
 Diarrhea
 Platelet count decreased
59.1
134.48
44.3
3551.7
47.28 to 70.92
107.58 to 161.38
28.5 to 54.6
3156.8 to 3980.2
Gamma
Gamma
Gamma
Gamma
Utility 0.66 0.59 to 0.735 Beta
AE duration, days
 Hand-foot syndrome
 Diarrhea
14
5
11.2 to 16.8
4 to 6
Gamma
Gamma
AE disutility
 Hand-foot syndrome
 Diarrhea
−0.116
−0.103
−0.139 to − 0.093
− 0.123 to − 0.082
Beta
Beta
Discount rate 0.03 0.00 to 0.05